Phase II Trial of Atragen and Interferon Alfa-2b in Patients With Advanced Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs AR 623 (Primary) ; Interferon alpha-2b (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 14 Feb 2017 Status changed from active, no longer recruiting to completed.
- 10 Aug 2005 New trial record.